Marinus Pharmaceuticals’ (MRNS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Tuesday morning, Benzinga reports. They currently have a $27.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on the stock. StockNews.com cut shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 6th. Oppenheimer reiterated a market perform rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Royal Bank of Canada reissued a sector perform rating and issued a $3.00 price objective (down from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday. Robert W. Baird reaffirmed a neutral rating on shares of Marinus Pharmaceuticals in a research note on Tuesday. Finally, Cantor Fitzgerald reissued an overweight rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average target price of $18.21.

Marinus Pharmaceuticals Trading Down 7.7 %

MRNS stock opened at $1.20 on Tuesday. The firm has a market cap of $65.92 million, a PE ratio of -0.46 and a beta of 0.91. The firm has a fifty day moving average price of $8.89 and a 200 day moving average price of $8.50. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07. Marinus Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $7.78 million. During the same period in the previous year, the business earned ($0.76) earnings per share. Sell-side analysts anticipate that Marinus Pharmaceuticals will post -2.43 earnings per share for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

A number of large investors have recently modified their holdings of MRNS. Ameritas Investment Partners Inc. bought a new position in Marinus Pharmaceuticals in the second quarter worth approximately $45,000. Quantbot Technologies LP purchased a new position in shares of Marinus Pharmaceuticals during the first quarter valued at $40,000. FMR LLC raised its holdings in shares of Marinus Pharmaceuticals by 1,887.9% in the first quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 4,210 shares in the last quarter. BluePath Capital Management LLC purchased a new stake in Marinus Pharmaceuticals in the third quarter worth about $38,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Marinus Pharmaceuticals by 383.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 5,003 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.